Render Target: SSR
Render Timestamp:
4/7/2025, 11:36:08 PM EDT
4/8/2025, 3:36:08 AM UTC
Commit: c91f970ca8df4f527662a05c7bd6e4d03c6fa173
XML generation date: 2025-03-07 13:09:15.735
Product last modified at: 2024-05-30T07:08:56.745Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: siRNA
PDP - Template ID: *******aa36529

SignalSilence® TRAF5 siRNA I #38805

Inquiry Info. # 38805

Please see our recommended alternatives.

    Supporting Data

    REACTIVITY H
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    CST recommends transfection with 100 nM SignalSilence® TRAF5 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

    Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.

    Storage

    SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.

    Product Description

    SignalSilence® TRAF5 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit TRAF5 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

    Quality Control

    Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

    Background

    TRAFs (TNF receptor-associated factors) are a family of multifunctional adaptor proteins that bind to surface receptors and recruit additional proteins to form multiprotein signaling complexes capable of promoting cellular responses (1-3). Members of the TRAF family share a common carboxy-terminal "TRAF domain", which mediates interactions with associated proteins; many also contain amino-terminal Zinc/RING finger motifs. The first TRAFs identified, TRAF1 and TRAF2, were found by virtue of their interactions with the cytoplasmic domain of TNF-receptor 2 (TNFRII) (4). The six known TRAFs (TRAF1-6) act as adaptor proteins for a wide range of cell surface receptors and participate in the regulation of cell survival, proliferation, differentiation, and stress responses.
    TRAF5 regulates signaling through binding to the cytoplasmic domains of TNFR famly members including CD40, CD27, CD30, OX40, and lymphotoxin-β receptor (5-10). Overexpression of TRAF5 induces NF-κB activation. Research studies show that cytoplasmic aggregates of TRAF5, as well as TRAF2, are found in Hodgkin-Reed-Sternberg cells, resulting in constitutive NF-κB activation (11).
    Studies of TRAF5 defecient mice suggest that it plays an important role in limiting Th2 immune responses that trigger T-cell mediated inflammatory diseases and asthma (12). Further studies indicate that TRAF5 binds to the IL-6 receptor gp130 and negatively controls Th17 differentation (13). In B-cells, TRAF5 negatively regulates toll-like receptor (TLR) mediated cytokine and antibody production (14).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.